Luye Pharma Group Ltd. (LYPHF)

Market Cap	934.44M -46.2%
Revenue (ttm)	902.33M -0.6%
Net Income	102.51M +75.4%
EPS	0.03 +64.5%
Shares Out	n/a
PE Ratio	9.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Open	0.2700
Previous Close	0.2700
Day's Range	0.2700 - 0.2700
52-Week Range	0.2041 - 0.3950
Beta	0.87
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,221
• Stock Exchange: OTCMKTS
• Ticker Symbol: LYPHF

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error